Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.50
+0.04 (0.70%)
At close: Aug 1, 2025, 4:00 PM
6.48
-0.01 (-0.23%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Sage Therapeutics Employees
As of December 31, 2024, Immatics had 682 total employees, including 554 full-time and 128 part-time employees. The number of employees increased by 147 or 27.48% compared to the previous year.
Employees
682
Change (1Y)
147
Growth (1Y)
27.48%
Revenue / Employee
$228,449
Profits / Employee
-$35,495
Market Cap
787.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682 | 147 | 27.48% |
| Dec 31, 2023 | 535 | 93 | 21.04% |
| Dec 31, 2022 | 442 | 61 | 16.01% |
| Dec 31, 2021 | 381 | 98 | 34.63% |
| Dec 31, 2020 | 283 | 56 | 24.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMTX News
- 2 months ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire
- 2 months ago - Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 3 months ago - Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - GlobeNewsWire
- 4 months ago - Immatics N.V.: Trading Below Cash, But Not Without Reason - Seeking Alpha
- 4 months ago - Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 9 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire
- 10 months ago - Immatics: A Promising TCR Pipeline - Seeking Alpha